St Jude Medical’s share price on the NYSE dropped by around 14% after it lowered profit targets as a result of weaker-than-expected third-quarter sales across the majority of its product categories. On October 6 – the day that St Jude announced its preliminary Q3 results – ...
Please Login to read the full article.
